MaxCyte MXCT Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $32.29M-14.3% | $33.03M-14.5% | $34.42M-24.5% | $35.75M-21.3% | $37.68M-14.5% | ||
| $6.29M-12.5% | $6.22M-12.4% | $6.89M+7.8% | $7.23M+37.4% | $7.19M+39.8% | ||
| $25.99M-14.7% | $26.8M-15.0% | $27.53M-29.8% | $28.53M-29.0% | $30.48M-21.7% | ||
| 80.5%-0.4pp | 81.2%-0.5pp | 80%-6.0pp | 79.8%-8.6pp | 80.9%-7.4pp | ||
| $18.78M-12.5% | $20.82M-6.3% | $22.1M-5.8% | $22.1M-9.4% | $21.45M-12.3% | ||
| $16.65M-33.4% | $18.92M-29.0% | $21.89M-20.1% | $24.16M-14.4% | $25M-10.9% | ||
| $25.56M-17.9% | $28.12M-5.3% | $29.84M-2.4% | $31.56M+6.4% | $31.12M+4.9% | ||
| $4.18M+1.1% | $4.23M+2.0% | $4.21M+0.5% | $4.18M-0.4% | $4.14M-0.1% | ||
| —— | $3.55M— | —— | —— | —— | ||
| $71.78M-12.1% | $78.7M-4.9% | $81.1M-5.3% | $82.01M-5.2% | $81.7M-5.3% | ||
| $71.78M-12.1% | $78.7M-4.9% | $81.1M-5.3% | $82.01M-5.2% | $81.7M-5.3% | ||
| -$45.79M+10.6% | -$51.9M-1.4% | -$53.57M-15.5% | -$53.48M-15.5% | -$51.22M-8.1% | ||
| -141.8%-5.9pp | -157.1%-24.6pp | -155.6%-53.9pp | -149.6%-47.7pp | -135.9%-28.4pp | ||
| $6.67M-29.3% | $7.27M-28.3% | $7.94M-25.5% | $8.7M-19.9% | $9.43M-12.9% | ||
| $6.67M-29.3% | $7.27M-28.3% | $7.94M-25.5% | $8.7M-19.9% | $9.43M-12.9% | ||
| -$39.12M+6.4% | -$44.63M-8.7% | -$45.63M-27.7% | -$44.77M-26.4% | -$41.79M-14.3% | ||
| —— | —— | —— | —— | —— | ||
| -$39.12M+6.4% | -$44.63M-8.7% | -$45.63M-27.7% | -$44.77M-26.4% | -$41.79M-14.3% | ||
| -121.2%-10.2pp | -135.1%-28.9pp | -132.6%-54.2pp | -125.2%-47.3pp | -110.9%-27.9pp | ||
| -$0.37+7.5% | -$0.43-10.3% | -$0.44-29.4% | -$0.43-26.5% | -$0.40-14.3% | ||
| -$0.37+7.5% | -$0.43-10.3% | -$0.44-29.4% | -$0.43-26.5% | -$0.40-14.3% | ||
| 426.3M+1.4% | 425.4M+1.6% | 423.8M+1.6% | 422.3M+1.7% | 420.5M+1.6% | ||
| 426.3M+1.4% | 425.4M+1.6% | 423.8M+1.6% | 422.3M+1.7% | 420.5M+1.6% | ||
| —— | $3.55M— | —— | —— | —— | ||
| $6.67M-29.3% | $7.27M-28.3% | $7.94M-25.5% | $8.7M-19.9% | $9.43M-12.9% | ||
| -$45.79M+10.6% | -$51.9M-1.4% | -$53.57M-15.5% | -$53.48M-15.5% | -$51.22M-8.1% | ||
| -$41.5M+11.6% | -$47.56M-1.4% | -$49.25M-17.2% | -$49.16M-17.3% | -$46.92M-8.9% | ||
| -$41.5M+11.6% | -$47.56M-1.4% | -$49.25M-17.2% | -$49.16M-17.3% | -$46.92M-8.9% | ||
| -128.5%-4.0pp | -144%-22.6pp | -143.1%-50.9pp | -137.5%-45.2pp | -124.5%-26.7pp | ||
| -$45.79M+10.6% | -$51.9M-1.4% | -$53.57M-15.5% | -$53.48M-15.5% | -$51.22M-8.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is MaxCyte's revenue?
- MaxCyte (MXCT) generated $32.3M in revenue over the trailing twelve months, down 14.3% year over year.
- Is MaxCyte profitable?
- MaxCyte is not currently profitable: it reported a net loss of $39.1M over the trailing twelve months, a -121.2% net margin.
- What are MaxCyte's profit margins?
- Gross margin is 80.5% and operating margin is -141.8%, with a -121.2% net margin.
- What is MaxCyte's earnings per share?
- MaxCyte's diluted EPS over the trailing twelve months is $-0.37.
- Where does MaxCyte's income statement data come from?
- Every line is extracted from MaxCyte's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
